AT2 receptor agonist C21 is primarily investigated for its potential therapeutic applications in cardiovascular and renal diseases. It is known to promote vasodilation, which can help in reducing blood pressure and improving blood flow. This makes it a candidate for treating hypertension and other conditions related to vascular dysfunction.

Additionally, C21 has shown promise in protecting against organ damage, particularly in the heart and kidneys. It may reduce inflammation and fibrosis, which are common pathways leading to chronic kidney disease and heart failure. Research is also exploring its role in neuroprotection, potentially aiding in the treatment of stroke and neurodegenerative disorders.

In experimental models, C21 has demonstrated anti-inflammatory and anti-apoptotic effects, suggesting its utility in conditions where tissue injury and inflammation are prevalent. Its ability to modulate the renin-angiotensin system further supports its potential in managing diseases linked to this pathway. Ongoing studies aim to validate its efficacy and safety in clinical settings.